ELSEVIER SCIENTIFIC PUBLISHERS IRELAND

Atherosclerosis 104 (1993) 233–235

ATHEROSCLEROSIS

Author index (Vol. 104)

Abate, N., Vega, G.L. and Grundy, S.M.
Variability in cholesterol content and physical properties of lipoproteins containing apolipoprotein B-100 (104) 159
Abbott, C., see Mackness, M.I. (104) 129
Achard, F., see Bénistant, C. (104) 27
Almario, R.U., see Kasim, S.E. (104) 147
Arrol, S., see Mackness, M.I. (104) 129
Aubó, C., see Pedro-Botet, J. (104) 87
Auclair, M., see Mazière, J.-C. (104) 213
Auguet, T., see Pedro-Botet, J. (104) 87

Bagdade, J.D., Lane, J.T., Subbaiah, P.V., Otto, M.E. and Ritter, M.C.
Accelerated cholesteryl ester transfer in noninsulin-dependent diabetes mellitus (104) 69
Bellosta, S., see Bernini, F. (104) 19
Bénistant, C., Achard, F., Marcelon, G. and Lagarde, M.
Platelet inhibitory functions of aortic endothelial cells. Effects of eicosapentaenoic and docosahexaenoic acids (104) 27
Berenson, G.S., see Freedman, D.S. (104) 37
Bernini, F., Didoni, G., Bonfadini, G., Bellosta, S. and Fumagalli, R.
Requirement for mevalonate in acetylated LDL induction of cholesterol esterification in macrophages (104) 19
Bonfadini, G., see Bernini, F. (104) 19
Bonithon-Kopp, C., Levenson, J., Scarabin, P.-Y., Guillanneuf, M.-T., Kirzin, J.-M., Malmejac, A. and Guize, L.
Longitudinal associations between plasma viscosity and cardiovascular risk factors in a middle-aged French population (104) 173
Byers, T., see Freedman, D.S. (104) 37

Chapman, M.J., see Guérin, M. (104) 195
Ciccarelli, R., see Porreca, E. (104) 137
Cohen, J., see Moliterno, D.J. (104) 223
Cordopatri, F.
A possible protective role of veins against atherosclerosis (104) 221
Cuccurullo, F., see Porreca, E. (104) 137

de Wit, E., see Lombardi, P. (104) 117
Di Febbo, C., see Porreca, E. (104) 137
Didoni, G., see Bernini, F. (104) 19
Dolphin, P.J., see Guérin, M. (104) 195
Durrington, P.N., see Mackness, M.I. (104) 129

Ehnholm, C., see Tervahauta, M. (104) 47
Elovson, J., see Kasim, S.E. (104) 147

Farhat, M.H.B., see Slimane, M.N. (104) 153
Frants, R.R., see Lombardi, P. (104) 117
Freedman, D.S., Wattigney, W.A., Srinivasan, S., Newman, W.P., III, Tracy, R.E., Byers, T. and Berenson, G.S.
The relation of atherosclerotic lesions to antemortem and postmortem lipid levels: the Bogalusa Heart Study (104) 37
Friedman, M.H. and Fry, D.L.
Arterial permeability dynamics and vascular disease (104) 189
Fry, D.L., see Friedman, M.H. (104) 189
Fumagalli, R., see Bernini, F. (104) 19

Grundy, S.M., see Abate, N. (104) 159
Guérin, M., Dolphin, P.J. and Chapman, M.J.
Familial lecithin:cholesterol acyltransferase deficiency: further resolution of lipoprotein particle heterogeneity in the low density interval (104) 195
Guillanneuf, M.-T., see Bonithon-Kopp, C. (104) 173
Guize, L., see Bonithon-Kopp, C. (104) 173

Haigle, J., see Mazière, J.-C. (104) 213
Hammami, M, see Slimane, M.N. (104) 153
Havekes, L.M., see Lombardi, P. (104) 117
Hayashi, K., Nakashima, K., Saeki, M., Kurushima, H., Kurokawa, J.-I., Kuga, Y., Nomura, S.-I., Ohkura, Y., Ohtani, H., Tanaka, K. and Kajiyama, G.
Identification of a functional receptor differing from the LDL receptor that catabolizes chylomicron remnant in Hep G2 cells (104) 105
Hoffer, M.J.V., see Lombardi, P. (104) 117

Ikeda, M., see Ikeda, U. (104) 61
Ikeda, U., Ikeda, M., Seino, Y., Takahashi, M., Kasahara, T., Kano, S. and Shimada, K.
Expression of intercellular adhesion molecule-1 on rat vascular smooth muscle cells by pro-inflammatory cytokines (104) 61

Janus, E.D., see Lam, K.S.L. (104) 183

Jauhiainen, M., see Tervahauta, M. (104) 47
Jen, K.-L.C., see Kasim, S.E. (104) 147
Jessen, M.E., see Moliterno, D.J. (104) 223

Kajiyama, G., see Hayashi, K. (104) 105
Kano, S., see Ikeda, U. (104) 61
Kasahara, T., see Ikeda, U. (104) 61
Kasim, S.E., Elovson, J., Khilnani, S., Almario, R.U. and Jen, K.-L.C.
Effect of lovastatin on the secretion of very low density lipoprotein lipids and apolipoprotein B in the hypertriglyceridemic Zucker obese rat (104) 147
Khilnani, S., see Kasim, S.E. (104) 147
Kirzin, J.-M., see Bonithon-Kopp, C. (104) 173
Kivinen, P., see Tervahauta, M. (104) 47
Kuga, Y., see Hayashi, K. (104) 105
Kung, A.W.C., see Lam, K.S.L. (104) 183
Kurokawa, J.-I., see Hayashi, K. (104) 105
Kurushima, H., see Hayashi, K. (104) 105

Lagarde, M., see Bénistant, C. (104) 27
Lam, K.S.L., Pang, R.W.C., Janus, E.D., Kung, A.W.C. and Wang, C.C.L.
Serum apolipoprotein(a) correlates with growth hormone levels in Chinese patients with acromegaly (104) 183
Lane, J.T., see Bagdade, J.D. (104) 69
Leuven, J.A.G., see Lombardi, P. (104) 117
Levenson, J., see Bonithon-Kopp, C. (104) 173
Lombardi, P., Hoffer, M.J.V., Top, B., de Wit, E., Leuven, J.A.G., Frants, R.R. and Havekes, L.M.
An acceptor splice site mutation in intron 16 of the low density lipoprotein receptor gene leads to an elongated, internalization defective receptor (104) 117

Maatoug, F., see Slimane, M.N. (104) 153
Mackness, M.I., Arrol, S., Abbott, C. and Durrington, P.N.
Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase (104) 129
Malmejac, A., see Bonithon-Kopp, C. (104) 173
Marcelon, G., see Bénistant, C. (104) 27
Mazière, C., see Mazière, J.-C. (104) 213
Mazière, J.-C., Myara, I., Salmon, S., Auclair, M., Haigle, J., Santus, R. and Mazière, C.
Copper and malondialdehyde-induced modification of high density lipoprotein and parallel loss of lecithin cholesterol acyltransferase activation (104) 213
Mittelman, A., see Vlasic, N. (104) 79
Moliterno, D.J., Jessen, M.E., Schueler, K. and Cohen, J.
Plasma lipoprotein(a) concentrations are not elevated by cardiopulmonary bypass (104) 223
Myant, N.B.
Familial defective apolipoprotein B-100: a review, including some comparisons with familial hypercholesterolaemia (104) 1
Myara, I., see Mazière, J.-C. (104) 213

Nakashima, K., see Hayashi, K. (104) 105
Newman, W.P., III, see Freedman, D.S. (104) 37
Nissinen, A., see Tervahauta, M. (104) 47
Nogués, X., see Pedro-Botet, J. (104) 87
Nomura, S.-I., see Hayashi, K. (104) 105

Ohkura, Y., see Hayashi, K. (104) 105
Ohtani, H., see Hayashi, K. (104) 105
Otto, M.E., see Bagdade, J.D. (104) 69

Pang, R.W.C., see Lam, K.S.L. (104) 183
Pedro-Botet, J., Sentí, M., Auguet, T., Nogués, X., Rubiés-Prat, J., Aubó, C. and Vidal-Barraquer, F.
Apolipoprotein(a) genetic polymorphism and serum lipoprotein(a) concentration in patients with peripheral vascular disease (104) 87
Pekkanen, J., see Tervahauta, M. (104) 47
Porreca, E., Ciccarelli, R., Di Febbo, C. and Cuccurullo, F.
Protein kinase C pathway and proliferative responses of aged and young rat vascular smooth muscle cells (104) 137
Pousse, H., see Slimane, M.N. (104) 153

Ramos, L., see Vlasic, N. (104) 79
Ritter, M.C., see Bagdade, J.D. (104) 69
Rubiés-Prat, J., see Pedro-Botet, J. (104) 87

Saeki, M., see Hayashi, K. (104) 105
Saito, J., see Shiina, T. (104) 95
Salmon, S., see Mazière, J.-C. (104) 213
Santus, R., see Mazière, J.-C. (104) 213
Scarabin, P.-Y., see Bonithon-Kopp, C. (104) 173
Schueler, K., see Moliterno, D.J. (104) 223
Seino, Y., see Ikeda, U. (104) 61
Sentí, M., see Pedro-Botet, J. (104) 87
Shiina, T., Terano, T., Saito, J., Tamura, Y. and Yoshida, S.
Eicosapentaenoic acid and docosahexaenoic acid suppress the proliferation of vascular smooth muscle cells (104) 95
Shimada, K., see Ikeda, U. (104) 61
Slimane, M.N., Pousse, H., Maatoug, F., Hammami, M. and Farhat, M.H.B.
Phenotypic expression of familial hypercholesterolaemia in Central and Southern Tunisia (104) 153
Srinivasan, S., see Freedman, D.S. (104) 37
Stemerman, M.B., see Vlasic, N. (104) 79
Stengård, J., see Tervahauta, M. (104) 47
Subbaiah, P.V., see Bagdade, J.D. (104) 69

Takahashi, M., see Ikeda, U. (104) 61
Tamura, Y., see Shiina, T. (104) 95
Tanaka, K., see Hayashi, K. (104) 105
Terano, T., see Shiina, T. (104) 95
Tervahauta, M., Pekkanen, J., Kivinen, P., Stengård, J., Jauhiainen, M., Ehnholm, C. and Nissinen, A.
Prevalence of coronary heart disease and associated risk factors among elderly Finnish men in the Seven Countries Study (104) 47

Top, B., see Lombardi, P. (104) 117
Tracy, R.E., see Freedman, D.S. (104) 37

Vega, G.L., see Abate, N. (104) 159
Vidal-Barraquer, F., see Pedro-Botet, J. (104) 87
Vlasic, N., Ramos, L., Mittelman, A. and Stemerman, M.B. Inhibition of smooth muscle cell proliferation and DNA synthesis by Vasoprin — a biological response modifier (104) 79

Wang, C.C.L., see Lam, K.S.L. (104) 183
Wattigney, W.A., see Freedman, D.S. (104) 37

Yoshida, S., see Shiina, T. (104) 95

ELSEVIER SCIENTIFIC
PUBLISHERS IRELAND

Atherosclerosis 104 (1993) 236–237

ATHEROSCLEROSIS

Subject index (Vol. 104)

Acromegaly, (104) 183
Acyl-CoA, (104) 19
Adaptation, (104) 189
Aging, (104) 137
Antibody MB19, (104) 1
Anti-proliferative effect, (104) 95
Apolipoprotein(a), (104) 183
Apolipoprotein A-I, (104) 195
Apolipoprotein B, (104) 195
Apolipoprotein B-100, (104) 1, 159
Apolipoproteins, (104) 47, 153
Arterial permeability, (104) 189
Atherogenesis, (104) 137, 189
Atherosclerosis, (104) 221

Biologic response modifier, (104) 79
Blood coagulation factors, (104) 47
Blood pressure, (104) 47

Cardiopulmonary bypass, (104) 223
Cardiovascular disease, (104) 47
Cardiovascular risk factors, (104) 173
Carotid arteries, (104) 221
Children, (104) 37
Cholesterol, (104) 37, 47, 159
Cholesterol acyltransferase, (104) 19
Cholesteryl ester, (104) 19
Cholesteryl ester transfer, (104) 69
Cholestyramine, (104) 1
Chylomicron remnant, (104) 105
Copper ions, (104) 213
Coronary artery disease, (104) 1
Coronary heart disease, (104) 47
Countercurrent heat exchange, (104) 221

Denaturing gradient gel electrophoresis, (104) 117
Diurnal changes, (104) 189
DNA specific activity, (104) 79
Docosahexaenioc acid, (104) 27, 95
Duplex scanning, (104) 221

Eicosapentaenoic acid, (104) 27, 95
Endothelium, (104) 27
Epidemiology, (104) 173

Familial defective apo B-100, (104) 1
Familial hypercholesterolaemia, (104) 1, 117, 153
Fatty streaks, (104) 37
Fibrous plaques, (104) 37

Growth hormone, (104) 183

HDL modification, (104) 213
Hemodynamics, (104) 189
Hemorheology, (104) 173
Hep G2 cells, (104) 105
Heparin affinity chromatography, (104) 195
High density lipoprotein, (104) 129
HMG-CoA reductase inhibitors, (104) 19, 147
3-Hydroxy-3-methylglutaryl coenzyme A, (104) 19

ImuVert, (104) 79
Intercellular adhesion molecule-1, (104) 61
Interleukin 1, (104) 61
Interleukin 6, (104) 61

LDL, (104) 159
LDL patterns, (104) 159
LDL receptor-related protein (LRP), (104) 105
Lecithin cholesterol acyltransferase, (104) 213
Lipid peroxides, (104) 95, 129
Lipoprotein(a), (104) 1, 87, 223
Lipoproteins, (104) 183
Lipoprotein-X, (104) 195
Longitudinal associations, (104) 173
Low density lipoprotein, (104) 129
Low density lipoprotein receptors, (104) 1, 117

Macrophages, (104) 19
Malondialdehyde, (104) 213
Models, (104) 189
Monocyte chemoattractant protein 1, (104) 61
Mutations, (104) 117

Noninsulin-dependent diabetes mellitus, (104) 69
NonLDL, (104) 159

Octreotide, (104) 183
Oxidation, (104) 129

Paraoxonase, (104) 129
Peripheral vascular disease, (104) 87
Phenotype, (104) 87
Plasma viscosity, (104) 173
Platelets, (104) 27
Polymerase chain reaction, (104) 117
Prostacyclin, (104) 27
Protein kinase C, (104) 137

Renal failure, (104) 195

Serum lipids, (104) 153
Smooth muscle cell, (104) 61
Smooth muscle cell proliferation, (104) 79
Statins, (104) 1

Tunisia, (104) 153

Vascular injury, (104) 79
Vascular smooth muscle cells, (104) 95
Vascular smooth muscle cells proliferation, (104) 137
Vasoprin, (104) 79
Very low density lipoprotein remnants, (104) 1
VLDL-apo B, (104) 147
VLDL-composition, (104) 147

Xanthoma, (104) 153

Zucker fa/fa rat, (104) 147